How much imatinib is enough?
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17444
Abstract: Discontinuation of imatinib treatment after a sustained deep molecular response enables a proportion of people with chronic myeloid leukaemia (CML) to achieve treatment-free remission (TFR). Other patients experience a molecular relapse with rising BCR-ABL1 levels… read more here.
Keywords: molecular relapse; treatment; relapse; trad study ... See more keywords